2 metanálises recentes destacam os benefícios de dupla antiagragação plaquetária com clopidogrel + aspirina por até 30 dias para pacientes com ataque isquêmico transitório de alto risco ou AVC isquêmico leve-moderado.

Metanálise 1: Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials – Stroke

Metanálise 2: Efficacy and Safety of Using Dual Versus Monotherapy Antiplatelet Agents in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials – Circulation (link para o resumo – $ para o texto completo)

Comentário: Dual vs. Monotherapy Antiplatelet Agents in Secondary Stroke Prevention – American College of Cardiology

Diretriz relacionada: Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke – The BMJ